AI-Pathway Companion Prostate Cancer from Siemens Healthineers Approved for Use in Europe as Medical Device

Siemens HealthineersAI-Pathway Companion Prostate Cancer(2), a digital companion from Siemens Healthineers to support clinical decision-making, has recently received the CE mark for use in the clinical pathway of prostate cancer, the second most common cancer (after lung cancer) affecting males worldwide.(3) The conformity mark confirms that the application AI-Pathway Companion Prostate Cancer is CE-compliant in accordance with Directive 93/42/EEC and can therefore be marketed in the EU as a medical device.

The AI-Pathway Companion product suite uses Artificial Intelligence, including Natural Language Processing4, to bring together data on a patient's disease and treatment status and presents it via an intuitive graphical user interface. AI-Pathway Companion Prostate Cancer also draws the physicians' attention to the appropriate treatment recommendations(1) from the prostate cancer guidelines of the European Association of Urology and the National Comprehensive Cancer Network5 to suit the patient's current treatment status.

"The AI-Pathway Companion helps multidisciplinary teams in particular with decision-making for diagnosis and treatment along the entire clinical pathway on the principles of evidence-based medicine. That means we can assist healthcare providers to put the individual patient at the center of the treatment process. We are very excited about AI-Pathway Companion as one of the first elements in our strategy of expanding to clinical decision making based on integrated diagnostics," says André Hartung, head of Diagnostic Imaging at Siemens Healthineers.

Decision-making for treatment and the follow-up process for prostate cancer is extremely complex and time consuming, since many individual patient parameters must be considered. This includes the stage at which the disease was discovered, whether it is a first diagnosis, whether various treatments have already been applied, and whether the tumor has reappeared following an initial treatment success. Lab results, like the PSA (prostate-specific antigen) value, pathology findings from a prostate punch biopsy, or the PI-RADS (Prostate Imaging - Reporting and Data System) score, which identifies the probability of a clinically significant carcinoma, and the Gleason score, which classifies the aggressiveness of a prostate tumor, are other examples of criteria used by physicians to help determine the next stages of examination and treatment. In the process, the physicians use evidence-based international medical guidelines which generally may run to well over 100 pages and often recommend appropriate, scientifically justified, and up-to-date processes for diagnostics and treatment; these also include the prostate cancer guidelines of the European Association of Urology(6) and the National Comprehensive Cancer Network(7). It is not hard to see that the mass of data contained in both the results and guidelines can pose a major challenge to decision-making.

AI-Pathway Companion Prostate Cancer helps match the data available for the individual patient with the guidelines to identify the recommended treatment approach and facilitate the appropriate disease management. The digital companion searches the patient record and other sources, like the hospital information system or PACS (Picture Archiving and Communication System), and compiles the longitudinal data for the cancer patient in question.(4) Natural Language Processing is used to extract and compile data relevant to the decision-making process from the radiology, pathology, genetics, and lab results, and present it via an intuitive user interface. The PI-RADS score is also automatically correlated with the Gleason score to help physicians estimate the aggressiveness of the tumor and determine the course of the disease on that basis. Algorithms search through the prostate cancer guideline for recommendations that suit the patient's individual disease status based on his or her current available data. The algorithms automatically show where the patient is in the pathway and recommend next options, including any missing information that is required.(8)

Based on this data, AI-Pathway Companion Prostate Cancer displays the patient's current clinical situation and offers guideline-based recommendations for further steps to provide treatment in accordance with the medical evidence. The digital companion can thus help multidisciplinary teams at tumor boards, for example, to make optimized decisions throughout the treatment process.

"Our multidisciplinary team (MDT) discussions can greatly vary in time. If a clinical decision support solution could integrate and display the patient context in a smart and standardized way, while providing evidence-based diagnosis and therapy recommendations, it could help make the discussions shorter and save time for all the MDT participants," says Prof Helge Seifert, MD Chairman, Clinic for Urology at University Hospital Basel.(9)

"I spend a lot of time entering patient information manually in our MDT solution. If this information could be integrated automatically and in a smart and standardized way, it would save us a lot of time and let us focus on what's important: the patient," says Christian Wetterauer, MD Senior Urologist at University Hospital Basel.(10)

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.

1. Depending on available input data
2. AI-Pathway Companion Prostate Cancer VA10A supports prostate cancer adenocarcinoma cases only. The product is not yet commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact the local Siemens Healthineers organization for further details.
3. Source: Rawla, P., Epidemiology of Prostate Cancer, World J Oncol. 2019 Apr; 10(2): 63-89, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497009/%204https://uroweb.org/guideline/prostate-cancer/
4. Feature supported by AI-Pathway Companion Connector.
5. AI-Pathway Companion Prostate Cancer VA10A supports NCCN and EAU guidelines.
6. https://uroweb.org/guideline/prostate-cancer/
7. https://www.nccn.org/professionals/physician_gls/default.aspx
8. Prerequisite for automatic patient specific mapping: All data is available as required per guideline.
9. Prof. Seifert is employed by an institution that receives financial support from Siemens Healthineers for collaborations.
10 Dr. Christian Wetterauer is employed by an institution that receives financial support from Siemens Healthineers for collaborations.

Most Popular Now

App Determines COVID-19 Disease Severity…

A new mobile app can help clinicians determine which patients with the novel coronavirus (COVID-19) are likely to have severe cases. Created by researchers at NYU College of Dentistry, the...

NHS Trust Revolutionises Access to Menta…

North Staffordshire Combined Healthcare NHS Trust has selected the DXC Open Health Connect platform from DXC Technology (NYSE: DXC) and is creating a blueprint that could dramatically reduce mental health...

FDA Permits Marketing of First Game-Base…

The U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The prescription-only...

HealthTunes Launches iOS App to Deliver …

HealthTunes has announceed the launch of the iOS App specifically created to help alleviate the mental health suffering of frontline healthcare workers. After months of fighting the pandemic, many frontline...

Philips Announces Collaboration with Ame…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has once again joined forces with the American Telemedicine Association (ATA) to help further the...

Bluetooth Technology, the Best Ally to D…

"Tracers have been and are essential to manage the pandemic. Today, the tracing is done by hand and this work is slow and inaccurate. However, as we have seen, technology...

Successful Debut for DMEA sparks

16 - 18 June 2020, Berlin, Germany. DMEA sparks opened, featuring a wide range of topics. Federal Minister of Health Jens Spahn kicked off events. In his interview he focused on...

Digital Mental Health support to be Prov…

SilverCloud, the leading digital therapeutics provider, has partnered with mental health charity Northpoint Wellbeing to co-develop a new digital therapy programme to alleviate anxiety in young people. Coming at a...

Siemens Healthineers Uses Artificial Int…

Siemens Healthineers introduces Ysio X.pree(1), the world's first intelligent X-ray system with integrated AI for optimizing the daily routine of image acquisition in radiography. To assist radiologists with the subsequent...

Siemens Healthineers Offers Flexible Tel…

With its teamplay myCare Companion software, the company is bringing a new and flexible telemedicine solution to the market that enables remote care for patients with chronic diseases. The teamplay...

Computer Modelling Predicts where Vaccin…

Researchers have developed a model that can estimate regional disease burden and the impact of vaccination, even in the absence of robust surveillance data, a study in eLife reveals. The report...

Andrea Fiumicelli Appointed as a CEO of …

Dedalus Group, leader in Europe and one of the world's leading players in clinical and healthcare information systems supporting clinical professionals and healthcare facilities thanks to a wide portfolio of...